

ALLE0014-103
17355CIP3

PATENT

**CLOSTRIDIAL NEUROTOXIN COMPOSITIONS AND MODIFIED
CLOSTRIDIAL NEUROTOXINS**

by

Lance E. Steward, Ester Fernandez-Salas, Todd Herrington, and K. Roger Aoki

CROSS REFERENCE

[0001] This application is a continuation-in-part of application serial number 10/163,106, filed June 4, 2003, which is a continuation-in-part of application serial number 09/910,346, filed July 20, 2001, which is a continuation-in-part of application serial number 09/620,840, filed July 21, 2000. All prior applications are incorporated herein by reference in their entireties.

BACKGROUND

[0002] The present invention relates to modified neurotoxins, particularly modified Clostridial neurotoxins, and use thereof to treat various conditions including conditions that have been treated using naturally occurring botulinum toxins.

[0003] The present invention also relates to a composition comprising an isolated or purified botulinum toxin light chain (or a part thereof) and an intracellular structure, such as a component of a mammalian plasma membrane.

[0004] Botulinum toxin, for example, botulinum toxin type A, has been used in the treatment of numerous conditions including pain, skeletal muscle conditions,